Twogee Biotech has completed a seed funding round of €2.16 million. Investors include the High-Tech Gründerfonds and Bayern Kapital. The round is complemented by strategic partners such as the AgriFoodTech Venture Alliance and Heinz Entsorgung, who will support the Munich startup in scaling.
With this funding, Twogee Biotech aims to accelerate the development and commercialization of its enzyme platform. The startup was founded in Munich in 2024 and develops custom enzyme solutions and production strains for industrial applications. The goal is to make biomass side and residual streams economically viable and unlock them as raw material sources for industrial companies.
Side streams are biogenic materials that arise as byproducts in industrial, agricultural, or waste management processes. These include plant residues or organic waste materials that have traditionally been underutilized or disposed of. Twogee Biotech converts these materials into second-generation raw materials using enzymes, particularly so-called 2G sugars.
These 2G sugars are residue-based and do not compete with food production. They serve as starting materials for chemical, bio- and synbiological processes and can replace fossil or food-based raw materials. For industrial companies, this creates the opportunity to continue using existing facilities while simultaneously transforming their raw material base.
Frank Wallrapp, CEO of Twogee Biotech:
“Many industrial waste streams contain significant untapped value creation potential. We help our partners unlock these opportunities with minimal integration effort and clear economic prospects.”
Expanding infrastructure and team
The startup is investing the capital raised primarily in expanding its infrastructure and team growth. At its Martinsried location near Munich, Twogee Biotech already operates its own laboratories and bioreactors. First minimum viable products are available, and paid pilot projects with industrial partners are underway.
Helge Jochens, CTO and co-founder:
“A substantial part of the funding flows into expanding our laboratories at the IZB with predictive bioreactor systems and strengthening our team with experienced process and scale-up experts. This ensures that our developments can be economically transferred to production scale at our customers’ facilities.”
Another component of the business model is a licensing approach that also enables local enzyme production at the customer’s site. This reduces costs and transportation emissions while building decentralized value chains.
With the completed seed funding, Twogee Biotech positions itself as a technology development partner for industrial companies that want to systematically utilize biomass side streams and gradually transition their raw material supply to low-CO2 alternatives.
